Retatrutide for Sale: 10 mg at $49.50, 30 mg at $125

Sort every listing you find into one of these four rows before you look at the price. The third column is the one that decides whether the listing is comparable to anything else.

The pattern is that disclosure and priceability are the same property. A format that hides the milligrams hides the price, whatever the sticker says.

Lyophilised powder in a sealed vial with one compound and one stated strength is the format the research market runs on, and the two sizes that dominate retatrutide listings are 10 mg and 30 mg.

Three properties make it the only priceable format. The strength is stated, so there is a denominator. The powder is dry, so you decide the concentration when you reconstitute rather than inheriting someone else's. And the batch code on the label can be matched against a certificate of analysis, so the stated strength is backed by something.

Ascension Peptides publishes two third-party certificates per batch: Kovera Labs on batches 03-05260628 and 43-05260628, tested 26 May 2026, and MZ Biolabs on batches 03-01260229 and 43-01260229, tested 6 February 2026. Certificates cover chromatographic purity and mass confirmation, and they describe the batch that was sampled rather than any individual vial.

What this format does not give you is pharmaceutical manufacturing. Research-grade material varies between suppliers, and part of the labelled mass in any lyophilised peptide can be counterion and residual excipient rather than peptide. Our introduction to peptides covers why that is normal for the class.

A blend puts two or more compounds in one vial and states a combined strength. If the ratio is not published, the amount of retatrutide in the vial is unknown, and an unknown numerator means there is no cost per milligram to calculate.

The table below is an illustrative arithmetic exercise, not a real listing. Take any blend sold at a $120.00 total for a stated 20 mg combined, and watch what the undisclosed ratio does to the figure that matters.

The spread across those rows is the point. Same vial, same price, same label, and the cost of a retatrutide milligram moves by 50% depending on a ratio the listing never told you. The last row is where most blend listings actually sit.

There is a second problem downstream. Reconstitution arithmetic assumes one compound at one strength, so a blend gives you a combined mg/mL that no longer maps cleanly onto either constituent. Our peptide calculator guide explains why every output depends on a single trustworthy milligram figure going in.

A pre-filled pen or a ready-to-use liquid cartridge is a finished dosage form. That is a meaningful thing to notice about a compound with no marketing authorisation, because a finished dosage form is a product presentation for administration rather than laboratory stock.

The arithmetic problem is separate and just as concrete. Reconstitution is where the researcher sets the concentration, and a pre-mix removes that choice. Unless the listing states both the concentration in mg/mL and the fill volume in mL, the total milligrams in the device are unknown, and you are back to a price with no denominator.

Stability is the third issue. A lyophilised cake is stable in a way a solution is not, which is why the research market sells powder and the buyer adds bacteriostatic water at the point of use. A liquid that has been in transit for an unknown time at an unknown temperature carries a history you cannot inspect.

Treat the format as information about the seller. A supplier offering retatrutide as a finished pen is not describing research material, and the FDA has published specific warnings about unapproved GLP-1 products marketed in this space.

Pharma grade, medical grade and premium grade have no standardised meaning on a research-peptide listing. No body issues those designations for this class of material, and no test corresponds to them. They are marketing words attached to a price.

The claim that does mean something is a numeric purity figure on a batch-matched certificate, and even that needs reading carefully. A purity result describes the proportion of the sample that eluted as the target peak on HPLC. It says nothing about identity, which is what mass spectrometry adds, and nothing about how much of the labelled mass is peptide rather than counterion.

So the useful question about any purity claim is not how high the number is but where it came from: which laboratory, which batch, which date, which method. A listing that answers all four is telling you something. A listing that says 99% in body text with no certificate behind it has told you nothing at all.

Price tiers built on grade language deserve the same scepticism. If a seller charges a premium for a pharma-grade tier and a lower price for a research tier, ask what analytical difference sits between them. Where the answer is a word rather than a second certificate, the tier is a pricing structure and the material is very likely identical. Divide both tiers by their milligrams and compare the two rates before assuming the expensive one is better.

Six disclosures, and the third column shows which calculation each one feeds. A missing disclosure is not a cosmetic gap, it removes a number from the chain.

Run this against any listing in under a minute. In practice most fail on the batch code, which is the cheapest disclosure to fake and the easiest to check.

With a stated strength and a discounted price, cost per milligram is one division: $49.50 ÷ 10 mg is $4.95, and $125.00 ÷ 30 mg is $4.17. The larger vial is about 16% cheaper per milligram.

The figure most buyers never calculate is what a partial vial does to that. Draws per vial is strength divided by draw size, rounded down, and the remainder is material you paid for and cannot use as a whole draw.

Real cost per draw is the vial price divided by the number of whole draws, so it absorbs the waste. At a 3 mg draw the 10 mg vial delivers three draws at $16.50 each rather than the $14.85 the per-milligram rate suggests, an 11% premium created entirely by the leftover milligram.

The 30 mg vial divides cleanly at 1, 2, 3, 5 and 6 mg, which is a quiet second reason it prices better. Our retatrutide price breakdown covers the tiers and shipping thresholds, and the reconstitution calculator converts any of these into concentration and syringe units.